Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt
Open Access
- 2 November 2014
- journal article
- research article
- Published by Taylor & Francis in Avian Pathology
- Vol. 43 (6) , 514-523
Abstract
The effectiveness of recombinant turkey herpesvirus avian influenza (A/swan/Hungary/4999/2006(H5N1)) clade 2.2 virus (rHVT-H5) vaccine was evaluated in two layer chicken breeds (White Bovans [WB] and Brown Shaver [BS]). One dose of rHVT-H5 vaccine was administered at day 1 and birds were monitored serologically (haemagglutination inhibition test) and virologically for 19 weeks. Maternally-derived antibody and post-vaccination H5 antibody titres were measured using the Chinese (A/Goose/Guangdong/1/96(H5N1)) HA and the Egyptian (A/chicken/Egypt/128s/2012(H5N1)) HA as antigens. The challenge was conducted at 19 weeks of age and on six experimental groups: Groups I (WB) and II (BS), both vaccinated and challenged; Groups III (WB) and IV (BS), both vaccinated but not challenged; Groups V and VI, unvaccinated specific pathogen free chickens, serving respectively as positive and negative controls. The challenge virus was the clade 2.2.1 highly pathogenic avian influenza H5N1 A/chicken/Egypt/128s/2012 at a dose of 106 median embryo infective dose. For both breeds, complete maternally-derived antibody waning occurred at the age of 4 weeks. The immune response to rHVT-H5 vaccination was detected from the sixth week. The seroconversion rates for both breeds reached 85.7 to 100% in the eighth week of age. Protection levels of 73.3%, 60% and 0% were respectively recorded in Groups I, II and V. No mortalities occurred in the unchallenged groups. Group I showed superior results for all measured post-challenge parameters. In conclusion, a single rHVT-H5 hatchery vaccination conferred a high level of protection for a relatively extended period. This vaccine could be an important tool for future A/H5N1 prevention/control in endemic countries. Further studies on persistence of immunity beyond 19 weeks, need for booster with inactivated vaccines, breed susceptibility and vaccinal response, and transmissibility are recommended.Keywords
This publication has 28 references indexed in Scilit:
- Effect of species, breed and route of virus inoculation on the pathogenicity of H5N1 highly pathogenic influenza (HPAI) viruses in domestic ducksVeterinary Research, 2013
- Coexpression of Avian Influenza Virus H5 and N1 by Recombinant Newcastle Disease Virus and the Impact on Immune Response in ChickensAvian Diseases, 2011
- Highly pathogenic avian influenza virus H5N1 from Egypt escapes vaccine-induced immunity but confers clinical protection against a heterologous clade 2.2.1 Egyptian isolateVaccine, 2011
- Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strainsVaccine, 2011
- Maternal immunity against avian influenza H5N1 in chickens: limited protection and interference with vaccine efficacyAvian Pathology, 2011
- An overview of the epidemic of highly pathogenic H5N1 avian influenza virus in Egypt: epidemiology and control challengesEpidemiology and Infection, 2011
- Passive Protection Afforded by Maternally-Derived Antibodies in Chickens and the Antibodies' Interference with the Protection Elicited by Avian Influenza–Inactivated Vaccines in ProgenyAvian Diseases, 2010
- Generation and Evaluation of a Newcastle Disease Virus–Based H9 Avian Influenza Live VaccineAvian Diseases, 2010
- Vaccination with Newcastle Disease Virus Vectored Vaccine Protects Chickens Against Highly Pathogenic H7 Avian Influenza VirusAvian Diseases, 2009
- Phenotype analysis of lymphoid cells in Marek's disease of CD4+or CD8+T‐cell‐deficient chickens: Occurrence of double negative T‐cell tumourAvian Pathology, 1997